An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

NCT06538207 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: ONO-4578
DRUG: ONO-4538
DRUG: Oxaliplatin
DRUG: Levofolinate
DRUG: Irinotecan
DRUG: Fluorouracil
DRUG: Gemcitabine
DRUG: Nab-Paclitaxel

Sponsor

Ono Pharmaceutical Co., Ltd.